Regeneron Pharmaceuticals, Inc. (REGN) Stock
REGN Key Statistics
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
CEO: Leonard S. Schleifer. Company website
REGN — Frequently Asked Questions
What is the REGN stock price today?
Regeneron Pharmaceuticals, Inc. (REGN) trades at $959.41, up 4.73% on the day, as of Nov 12, 2026 09:32 UTC.
What is Regeneron Pharmaceuticals, Inc.'s market cap?
Regeneron Pharmaceuticals, Inc. has a market capitalisation of $99.23B, calculated from the live REGN share price and shares outstanding.
What is the P/E ratio of REGN?
REGN trades at a trailing P/E of 21.18, from earnings per share of $45.29 over the last twelve months.
How much revenue does Regeneron Pharmaceuticals, Inc. make?
Regeneron Pharmaceuticals, Inc. generated revenue of $16.90B over the trailing twelve months, which puts the stock at 5.87 times sales.
Does REGN pay a dividend?
Yes. Regeneron Pharmaceuticals, Inc. pays a dividend yielding 0.47% on the current share price.
What is the 52-week range for REGN?
REGN has traded between $591.52 and $991.73 over the past 52 weeks, and the last price is 3.3% below that high.
Is Regeneron Pharmaceuticals, Inc. profitable?
Yes. Regeneron Pharmaceuticals, Inc. keeps 28.51% of revenue as net income over the trailing twelve months.
What is the analyst price target for REGN?
Wall Street analysts rate REGN Buy, with an average price target of $887.79, 7.5% below the current price.
What sector is Regeneron Pharmaceuticals, Inc. in?
Regeneron Pharmaceuticals, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Regeneron Pharmaceuticals, Inc.?
Leonard S. Schleifer is the chief executive of Regeneron Pharmaceuticals, Inc., which employs 15,410 people.
Where can I track REGN in real time?
QFI Terminal shows REGN with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See REGN live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open REGN in Terminal See plans